Alector (ALEC) Operating Margin (2018 - 2026)
Alector (ALEC) reported Operating Margin of 2382.31% for Q1 2026, down 116579.0% year-over-year from N/an in Q1 2025, and down 271.85% on a QoQ basis from 1386.26% in Q4 2025.
Alector (ALEC) has 9 years of Operating Margin data on file, last reported at 2382.31% in Q1 2026.
- Quarterly Operating Margin fell 116579.0% year-over-year to 2382.31% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 55.41% (up 10985.0% YoY) and the FY2025 annual result came in at 142.46%, up 174.0% from the prior year.
- Operating Margin eased to 2382.31% in Q1 2026 per ALEC's latest filing, from 1386.26% in the prior quarter.
- Across five years, Operating Margin topped out at 1386.26% in Q4 2025 and bottomed at 2382.31% in Q1 2026.
- The 5-year median for Operating Margin is 302.83% (2023), against an average of 348.85%.
- The widest annual swing landed in 2025, when Operating Margin soared 139962 bps; it then plunged 116579 bps in 2026.
- Tracing ALEC's Operating Margin over 5 years: stood at 383.92% in 2022, then surged by 234 bps to 514.15% in 2023, then tumbled by 103 bps to 13.36% in 2024, then soared by 10473 bps to 1386.26% in 2025, then tumbled by 272 bps to 2382.31% in 2026.
- Per Business Quant, the three latest ALEC Operating Margin figures stand at 2382.31% (Q1 2026), 1386.26% (Q4 2025), and 1153.62% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.02% |
| 10 | Alector | 238.87 Mn | 32.36 Mn | - | -2,382.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,382.31% |
| Dec 31, 2025 | 1,386.26% |
| Sep 30, 2025 | -1,153.62% |
| Jun 30, 2025 | -433.55% |
| Mar 31, 2025 | -1,216.52% |
| Dec 31, 2024 | -13.36% |
| Sep 30, 2024 | -315.70% |
| Jun 30, 2024 | -302.37% |
| Mar 31, 2024 | -275.01% |
| Dec 31, 2023 | 514.15% |
| Sep 30, 2023 | -555.31% |
| Jun 30, 2023 | -6.38% |
| Mar 31, 2023 | -302.83% |
| Dec 31, 2022 | -383.92% |
| Sep 30, 2022 | -321.49% |
| Jun 30, 2022 | 11.87% |
| Mar 31, 2022 | -180.29% |
| Dec 31, 2021 | -185.77% |
| Sep 30, 2021 | 69.25% |
| Jun 30, 2021 | -842.34% |
| Mar 31, 2021 | -1,280.66% |
| Dec 31, 2020 | 2,111.44% |
| Sep 30, 2020 | -910.38% |
| Jun 30, 2020 | -1,469.68% |
| Mar 31, 2020 | -586.78% |
| Dec 31, 2019 | -538.94% |
| Sep 30, 2019 | -1,266.65% |
| Jun 30, 2019 | -392.54% |
| Mar 31, 2019 | -370.40% |
| Dec 31, 2018 | -207.95% |
| Sep 30, 2018 | -258.57% |
| Jun 30, 2018 | -172.05% |
| Mar 31, 2018 | -187.50% |